Evaluation of the effectiveness and transferability of the digital health platform (ProACT) to support home-based multimorbidity self-management in Europe
| ISRCTN | ISRCTN34134007 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN34134007 |
- Submission date
- 05/01/2023
- Registration date
- 20/01/2023
- Last edited
- 28/01/2025
- Recruitment status
- No longer recruiting
- Overall study status
- Ongoing
- Condition category
- Other
Plain English Summary
Background and study aims
Older persons with multimorbidity (PwMs) face considerable challenges in managing their conditions. They must monitor symptoms, take medications, and coordinate with care providers, to name just a few tasks. They must also manage their conditions despite the limitations of healthcare systems; systems traditionally designed to support those with single conditions, faced with an ageing population amongst whom multimorbidity is increasingly prevalent. One potential solution is to empower PwMs, using digital health, to self-manage their conditions with support. However, research examining digital solutions in this context is limited. The SEURO trial, upon which this study builds, is one of the few studies to test and demonstrate at a proof-of-concept level the potential utility of a digital health solution, ProACT, in facilitating multimorbidity management in older persons. The aim of this study is to examine the effectiveness and implementation of the updated personalised ProACT platform, combined with the ProACT-service care network and clinical triage service support, in comparison to the updated standardised ProACT platform, absent ProACT-service care network and clinical triage service support, and in comparison to standard care. The completion of this study will also facilitate the realisation of wider project aims: to evaluate the key factors necessary to prepare any EU region to implement and scale innovative, people-centric, digitally integrated health and social care solutions for multiple disease management.
Who can participate?
Persons aged 65 years old and over with two or more of the following conditions: diabetes; chronic respiratory disease (i.e., COPD, chronic bronchitis, emphysema, or chronic asthma); chronic heart disease, coronary artery disease, or cardiovascular disease (i.e., hypertension, atherosclerosis, angina, or arrhythmia); and chronic heart failure.
Care Network members (CNs; i.e., informal carers, formal carers and formal care quality assistants, and healthcare professionals).
What does this study involve?
PwMs will be randomly assigned to one of three trial arms. Those assigned to Trial Arm 1 will receive measuring devices relevant to their conditions (e.g., a pulse oximeter), the personalised ProACT CareApp, and a tablet device upon which they can view the CareApp. They will also receive a ProACT-service care network and clinical triage service support. Those assigned to Trial Arm 2 will receive measuring devices relevant to their conditions, the standardised ProACT CareApp, and a tablet device. Those assigned to Trial Arm 3 will continue to manage their healthcare as usual.
All PwMs will complete questionnaires at the beginning, once per month during, and at the end of their trials. A selection of Trial Arm 1 and 2 PwMs will participate in interviews at the beginning and end of their trials. Trial Arm 1 and 2 PwMs’ system use data (e.g., how often they use the CareApp) and system data (e.g., symptom measurements) will be collected throughout their trials.
CNs will receive access to a customised ProACT CareApp, through which they can view their PwM’s health and well-being data and educational material. They will also complete questionnaires at the beginning and end of their trials, a selection will participate in interviews at the end of their trials, and their system-use data will be collected throughout their trials.
Healthcare organisation management who oversee the delivery of ProACT will complete questionnaires several months prior to, immediately prior to, and after the trial; a selection will also participate in interviews after the trial. A selection of healthcare organisation staff who facilitate the delivery of ProACT during the trial will participate in interviews after it, as will clinical triage service nurses.
What are the possible benefits and risks of participating?
ProACT may help Trial Arm 1 and 2 PwMs to manage their conditions; ProACT-service care network and clinical triage service support may also facilitate improved support for Trial Arm 1 PwMs, and enhanced well-being amongst informal carers (e.g., due to reduced carer burden).
If Trial Arm 1 and 2 PwMs have never used a tablet device, they will have the opportunity to learn how, and if they do not have an internet connection, they will receive one for six months.
Trial Arm 1 and 2 PwMs may find it inconvenient to use the measuring devices. However, the harm of such inconvenience is transient, and they will be free not to use particular devices.
Monitoring their health and well-being may cause undue anxiety. However, to minimise this risk, the role of ProACT will be clearly explained: it is to be used as a self-management tool, as part of which PwMs can learn to better understand their baseline symptoms and what is ‘normal’ for them. This may facilitate a reduction in their anxiety. Should they have any concerns, the researchers will be happy to talk at any time. If they are concerned about their health, they will be encouraged to seek medical advice, as they usually would. They will also be free to withdraw from the study at any time.
For Trial Arm 1 PwMs, a clinical triage service will view their vital signs. However, they will be informed that they should follow their usual response procedures if they observe changes in their vital signs or feel unwell (e.g., they should contact their GP). In addition, they will be informed that the clinical triage service will operate during normal working hours only and will no longer be available after the conclusion of their trials. Trial Arm 2 PwMs will also be informed that they should follow their usual response procedures if they observe changes in their vital signs or feel unwell.
Participants will be asked to complete questionnaires and take part in interviews. Some may find it upsetting to answer questions about issues related to living with chronic conditions or caregiving. They will be informed that they can decline to answer any question and that they can withdraw from the study at any time without giving a reason. The researchers will be available to discuss any concerns.
Where is the study run from?
The study will be implemented across Ireland, Belgium and Sweden
When is the study starting and how long is it expected to run for?
May 2021 to November 2025
Who is funding the study?
SEURO received funding from the European Union’s Horizon 2020 (H2020) research and innovation programme under Grant Agreement No. 945449
Who is the main contact?
Dr John Dinsmore (Project Coordinator/Lead Principal Investigator), dinsmorj@tcd.ie (Ireland)
Dr Julie Doyle (Trial Lead/Partner Principal Investigator), julie.doyle@dkit.ie (Ireland)
Contact information
Principal Investigator
School of Nursing and Midwifery
Trinity College Dublin
Dublin
D02 PN40
Ireland
 ORCID ID |
0000-0001-8387-3496 |
|---|---|
| Phone | +35318964155 |
| dinsmorj@tcd.ie |
Principal Investigator
Netwell/CASALA
Dundalk Institute of Innovation and Technology
Dundalk
A91 K584
Ireland
| ORCID ID |
0000-0003-4017-6329 |
|---|---|
| Phone | +353 (0) 42 9370115 |
| julie.doyle@dkit.ie |
Study information
| Study design | 12-month multi-site mixed-methods study comprising a pragmatic-randomized controlled trial and process evaluation |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised controlled trial |
| Study setting(s) | Community |
| Study type | Other |
| Participant information sheet | 42997_PIS.pdf |
| Scientific title | Scaling European citizen-driven transferable and transformative digital health: a multi-site effectiveness-implementation hybrid trial of the Digital Health Platform ProACT to support older adults managing multiple chronic health conditions (multimorbidity) in Europe |
| Study acronym | SEURO |
| Study hypothesis | 1. To evaluate the impact of the ProACT platform on people with multimorbidities QoL and HCU (i.e., the trial primary outcomes). Participants in each trial arm will be compared with these outcome variables 2. To evaluate the cost-effectiveness of the personalised ProACT CareApp with the care network and triage support in comparison to the non-personalised ProACT CareApp and control group 3. To explore via a mixed methods approach (analysis of system and questionnaire data and interviews with participants) the potential impact of ProACT on multimorbidity self-management 4. To evaluate the impact of the ProACT platform on informal carers’ caring burden 5. To evaluate participants’ (people with multimorbidity and care networks) overall experiences with the ProACT platform in managing multimorbidity. Data collected from participants in Trial Arms 1 and 2 will also be compared. Furthermore, to explore the impact of contextual factors (e.g., participants’ conditions, age, and socioeconomic status; care network participants’ motivation to take part in the trial) on the fidelity of use and use outcomes (e.g., reach, uptake, and acceptability) 6. To understand how ProACT is implemented and delivered in healthcare settings, and to identify systematic differences and variations in delivery 7. To evaluate via the process evaluation organisational readiness to transfer and optimise a digital health solution as part of the care delivery 8. To evaluate whether trial outcomes can inform future analysis of the impact of digital solution implementation in practice |
| Ethics approval(s) | 1. Approved 23/12/2021, Swedish Ethical Review Authority (Etikprövningsmyndigheten, Box 2110, 750 02, Uppsala, Sweden; +46 0104750800; registrator@etikprovning.se), ref: 2021-05368-01 2. Approved 01/07/2022, Trent College Dublin Faculty of Health Sciences Research Ethics Committee (Faculty of Health Sciences, Chemistry Building, Trinity College Dublin, The University of Dublin, Dublin 2, Ireland, UK; +35318964255; ldohert@tcd.ie), ref: 220504 3. Approved 07/07/2022, DkIT School of Health and Science Research Ethics Committee (Dundalk Institute of Technology, Dublin Road, Dundalk, County Louth, A91 K584, Ireland; +353429370200; dolores.mcgill@dkit.ie), ref: none available 4. Approved 20/07/2022, HSE NorthEast Research Ethics Committee (Bective Street, Kells, County Meath, A82 NX32, Ireland; +353494377343; consumeraffairs.hsedne@hse.ie), ref: REC/22/026 5. Approved 22/07/2022, Caredoc Ethics Committee; Caredoc, St. Dympna’s Hospital, Athy Road, Carlow, County Carlow, R93 DE62, Ireland; +353599138199; info@caredoc.ie), ref: none available 6. Approved 26/09/2022, Blackrock Clinic Ethics Committee; Blackrock Clinic, Rock Road, Blackrock, Co. Dublin, A94 E4X7, Ireland; +35312832222; info@blackrock-clinic.com), ref: none available 7. Approved 28/09/2022, Universitair Ziekenhuis Brussel Ethics Committee; Commissie Medische Ethiek, Laarbeeklaan 101, 1090 Brussel, Belgium; +3224775584; commissie.ethiek@uzbrussel.be), ref: EC-2022-246 |
| Condition | Multimorbidity consisting of two or more of any of the following: 1. Diabetes 2. Chronic Respiratory Disease (i.e., COPD, Chronic Bronchitis, Emphysema, and Chronic Asthma) 3. Chronic Heart Disease, Coronary Artery Disease, and Cardiovascular Disease (i.e., Hypertension, Atherosclerosis, Angina, and Arrhythmia) 4. Chronic Heart Failure |
| Intervention | This 12-month multi-site trial will adopt a Type 1 Effectiveness-Implementation Hybrid design, which will comprise a pragmatic-Randomised Controlled Trial and process evaluation to assess the effectiveness and implementation of ProACT in real-world conditions respectively, with the person with multimorbidity (PwM), recruited on an ongoing basis during the first six months of the trial, randomly assigned to one of three unblinded trial arms for six months: 1.0. Trial Arm 1 participant receives: 1.1. Tablet device and suite of sensors devices. These include ‘off-the-shelf’ devices that are used to collect health and wellbeing data from PwM in their homes (e.g., blood glucose, blood pressure, pulse oximetry, heart rate, weight, sleep, and/or activity measures). 1.2. Personalised ProACT CareApp 1.3. Ability to link in with their Care Network (informal carer, formal carer and healthcare professional) via customised ProACT CareApp user interfaces tailored to each key stakeholder group 1.4. Clinical triage service and technical Helpdesk support (Mon to Fri 9am to 5pm) Details on personalised ProACT CareApp: Accessed via an interactive device (e.g., a tablet or smartphone), this app displays users’ health and wellbeing data as derived from the different measuring devices. To support PwM self-managing their health and wellbeing, the CareApp provides feedback (e.g., feedback on health status including exacerbations), tools (e.g., medication management tools and goal-setting features), and personalised educational content (e.g., written, audio, and visual content sourced from relevant, reliable, and trusted organisations localised by region) that is contextualised to the person’s current health and wellbeing status. It also provides participants with the option to self-report through a series of questions about their health and wellbeing (e.g., for those parameters not easily measured by a sensing device, such as breathlessness, mood etc.) Trial Arm 1 will receive: Tablet device and suite of sensors, Personalised ProACT CareApp, have the ability to include their Care Network via, be in receipt of clinical triage service and technical Helpdesk support (Mon to Fri 9am to 5pm). 2.0. Trial Arm 2 participant receives: 2.1. Tablet device and suite of sensors devices. These include ‘off-the-shelf’ devices that are used to collect health and wellbeing data from PwM in their homes (e.g., blood glucose, blood pressure, pulse oximetry, heart rate, weight, sleep, and/or activity measures). 2.2. Standard ProACT CareApp with no personalisation. The primary differences in the CareApp for those in trial arm 2 are that exacerbations are not highlighted and educational content is not contextualised to current status, therefore representing a more standard application that might be downloaded from an app store. 2.3. Technical Helpdesk support (Mon to Fri 9am to 5pm). 3.0. Trial Arm 3 participant receives: Usual care (no technology) |
| Intervention type | Behavioural |
| Primary outcome measure | 1. Quality of Life measured using the EuroQol EQ-5D-5L questionnaire and Control, Autonomy, Self-realisation and Pleasure Scale (CASP-19) at T1 (baseline) and T7 (at the end of a PwM’s 6-month trial period) 2. Healthcare Utilisation measured using a SEURO trial-designed Healthcare Utilisation questionnaire at the beginning of the trial period, once per month during, and at the end of a PwM’s 6-month trial period (at T1, T2, T3, T4, T5, T6, and T7) Focus is on exploring cost effectiveness using these outcomes. |
| Secondary outcome measures | Persons with multimorbidity (PwMs): 1. Type, number, and perceived burden of comorbidities measured, measured using the Comorbidity Index, baseline and 6 months post-baseline 2. Self-care, the belief in one’s ability to self-care, and the self-care of chronic illness, measured using the Self-Care Chronic Illness Inventory, baseline and 6 months post-baseline 3. Medication adherence, measured using the MARS-5, baseline and 6 months post-baseline 4. Health literacy, measured using the HLS-EU-Q16, baseline and 6 months post-baseline 5. Digital health literacy, measured using the eHealth Literacy Scale, baseline and 6 months post-baseline 6. Digital literacy, measured using the MDPQ-16, baseline and 6 months post-baseline 7. Technology acceptance, measured using the UTAUT2, at 6 months 8. The usability of the ProACT technology, measured using the User Burden Scale, at 6 months 9. The utility of and experiences with ProACT, measured using a SEURO-trial-designed ProACT Impact Evaluation questionnaire, at 6 months 10. The health support system of PwMs (e.g., the individuals in PwMs’ care networks and the role they play), measured using a SEURO-trial designed Health Support System questionnaire, baseline and 6 months post-baseline 11. Expectations about ageing (e.g., expectations about physical health, mental health, and cognitive function), measured using the ERA-12, at baseline and 6 months post-baseline 12. Self-management effectiveness (e.g., setting and meeting activity goals and controlling symptoms), measured daily using system data throughout the participants’ trial period (baseline to 6 months post-baseline) and by interview at 6 months 13. Engagement with ProACT, measured daily using system data throughout the participants’ trial period (baseline to 6 months post-baseline) and by interview, at 6 months 14. Experiences with ProACT (e.g., the usability, accessibility, and acceptability of, and engagement, satisfaction, and overall experiences with ProACT) measured daily using system data throughout the participants’ trial periods (baseline to 6 months post-baseline) and by interview at 6 months 15. The care network of PwMs (e.g., the quality of support), measured using interviews, at baseline and 6 months post-baseline 16. Demographic data (e.g., gender, date of birth, and marital status), which will be used to perform inferential statistics and to include as covariates during the analysis of primary and secondary outcomes etc., measured using a SEURO-trial designed Demographics questionnaire, at baseline. Care Network Members: 1. Carer burden, measured using the Zarit Burden Interview, at baseline and 6 months post-baseline. This measure completed by informal carers only. 2. The usability of the ProACT technology, measured using the User Burden Scale at 6 months. 3. The utility of and experiences with ProACT, measured using a SEURO trial-designed questionnaire at 6 months. 4. Daily engagement with ProACT measured using system data throughout the participants’ trial periods (baseline to 6 months post-baseline) 5. Experiences with ProACT (e.g., the usability, accessibility, and acceptability of, and engagement, satisfaction, and overall experiences with ProACT), explored by interview, at 6 months. 6. Demographic data, collected using a SEURO-trial designed Demographics questionnaire, at baseline. Healthcare Organisations: 1. Healthcare organisations’ administrative data, which will be used to explore, for instance, the factors that differentiate between organisations that do and do not implement and deliver ProACT with fidelity, measured using a SEURO-trial designed questionnaire prior to the commencement of the trial, at baseline and 12 months post-baseline. 2. Healthcare organisations’ preparedness for digital health solution transfer, measured using the ProTransfer questionnaire, measured at least 4-6 months pre-baseline, baseline and 12 months post-baseline 3. Experiences of ProACT (e.g., the reach, uptake, and fidelity of implementation of, the usability, accessibility, and acceptability of, and engagement, satisfaction, and overall experiences with ProACT), measured using an interview, at 12 months post-baseline Clinical Triage Service Nurses: 1. Daily engagement with ProACT (e.g., the number of calls made by nurses to PwMs in response to alerts) measured using system data throughout the trial (baseline to 12 months post-baseline). This data may also be indicative of PwMs’ self-management efforts and outcomes 2. Experiences with ProACT (e.g., the usability, accessibility, and acceptability of, and engagement, satisfaction, and overall experiences with ProACT), measured using an interview, at 12 months post-baseline |
| Overall study start date | 03/05/2021 |
| Overall study end date | 02/11/2025 |
Eligibility
| Participant type(s) | Mixed |
|---|---|
| Age group | Mixed |
| Lower age limit | 65 Years |
| Sex | Both |
| Target number of participants | 720 participants with multimorbidity; a maximum of 1500 care network participants |
| Participant inclusion criteria | Participants with multimorbidity must: 1. Be aged 65 years old and over 2. Possess sufficient cognitive capacity to provide written informed consent 3. Have at least 2 of the following conditions: diabetes, chronic respiratory disease (e.g. chronic obstructive pulmonary disease (COPD), chronic asthma), chronic heart failure, chronic heart disease (e.g., coronary artery disease, cardiovascular disease (including hypertension, atherosclerosis, angina or arrhythmia)) For care network participants to be included, the person with multimorbidity must provide consent for their participation. Care network participants must: 1. Be aged 18-90 years old and over 2. Be providing support to a consented participant with multimorbidity in trial arm 1 (if they are an informal carer, they must be providing support to a participant with multimorbidity for at least six months; and if they are a formal carer, formal care Quality Assistant, or healthcare professional, they must be formally recognised as such and possess at least two years’ experience of professionally working in a relevant health or primary care setting with people with multimorbidity with the same health conditions as those involved in the current trial) 3. Have access to a tablet, smartphone, or computer with an internet connection 4. Possess the skills to use an internet-based application or website 5. Possess sufficient cognitive capacity to provide written informed consent Partner organisation management and staff must: 1. Be aged 18 or older 2. Be overseeing and/or implementing the delivery of ProACT to their clients with multimorbidity 3. Have access to a tablet, smartphone, or computer with an internet connection 4. Possess the skills to use an internet-based application or website |
| Participant exclusion criteria | Does not meet inclusion criteria |
| Recruitment start date | 23/01/2023 |
| Recruitment end date | 02/05/2025 |
Locations
Countries of recruitment
- Belgium
- Ireland
- Sweden
Study participating centres
St. Dympna’s Hospital
Athy Road
Carlow
R93 DE62
Ireland
Furze Road
Sandyford Business Park
Dublin
Dublin 18
Ireland
Blackrock
Dublin
A94 E4X7
Ireland
Kells
A82 NX32
Ireland
Informatikenheten
By 24A
plan 3
Umeä
SE-90185
Sweden
Gent
9052
Belgium
Sponsor information
University/education
Office of the Dean of Research
House 1
Dublin 2
D02 PN40
Ireland
| Phone | +353 1 896 1398 |
|---|---|
| office.dean.res@tcd.ie | |
| Website | https://www.tcd.ie |
"ROR" |
https://ror.org/02tyrky19 |
University/education
Dublin Road
Marshes Upper
Dundalk
A91 K584
Ireland
| Phone | +353 42 937 0200 |
|---|---|
| julie.doyle@dkit.ie | |
| Website | https://www.dkit.ie |
|
"ROR" |
https://ror.org/01800zd49 |
Research organisation
imec-SMIT-VUB
Boulevard de la Plaine 9
1050 Etterbeek
Pleinlaan 9 (2nd floor)
Brussels
1050 Brussels
Belgium
| Phone | +32 2 614 85 40 |
|---|---|
| An.Jacobs@vub.be | |
| Website | https://smit.vub.ac.be |
|
"ROR" |
https://ror.org/006e5kg04 |
Government
Tvistevägen 48
Umeå
907 37
Sweden
| Phone | +46 073-0681877 |
|---|---|
| kenth.soderstrom@regionvasterbotten.se | |
| Website | https://www.regionvasterbotten.se |
|
"ROR" |
https://ror.org/04xvhsp09 |
Funders
Funder type
Government
Government organisation / National government
- Alternative name(s)
- EU Framework Programme for Research and Innovation, Horizon 2020 - Research and Innovation Framework Programme, European Union Framework Programme for Research and Innovation
Results and Publications
| Intention to publish date | 02/05/2026 |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Not expected to be made available |
| Publication and dissemination plan | Planned publication in a high-impact peer-reviewed journal |
| IPD sharing plan | The datasets generated during and/or analysed during the current study are not expected to be made available. No trial data will be made openly available. Due to the personal nature of the data collected, data will not be available outside of the trial site partners within the consortium. In addition, although data will be pseudonymised, there is risk that individuals could be identified from their data. Hence, even pseudonymised data cannot be made openly available. While these datasets will not be made openly available, the possibility of making them discoverable for transparency will be investigated throughout the SEURO project. If any changes are made this will be updated with outcomes later in the project timeline. |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Participant information sheet | 20/01/2023 | No | Yes | ||
| Participant information sheet | 20/01/2023 | No | Yes |
Additional files
Editorial Notes
28/01/2025: The following changes were made:
1. The recruitment end date was changed from 01/11/2024 to 02/05/2025.
2. The overall study end date was changed from 02/05/2025 to 02/11/2025.
3. The intention to publish date was changed from 02/11/2025 to 02/05/2026.
10/07/2024: The following changes were made to the trial record:
1. The recruitment end date was changed from 02/07/2024 to 01/11/2024.
2. The overall end date was changed from 02/01/2025 to 02/05/2025.
3. The intention to publish date was changed from 02/05/2025 to 02/11/2025.
4. The plain English summary was updated to reflect these changes.
11/12/2023: The following changes have been made:
1. The recruitment end date has been changed from 31/12/2023 to 02/07/2024.
2. The overall study end date has been changed from 02/05/2024 to 02/01/2025 and the plain English summary updated accordingly.
3. The intention to publish date has been changed from 31/12/2024 to 02/05/2025.
4. The IPD sharing statement has been added.
14/08/2023: The following changes have been made:
1. The recruitment end date has been changed from 30/06/2023 to 31/12/2023.
2. The overall study end date has been changed from 31/12/2023 to 02/05/2024 and the plain English summary updated accordingly.
3. The intention to publish date has been changed from 01/09/2024 to 31/12/2024.
23/03/2023: The intention to publish date has been changed from 01/02/2023 to 01/09/2024.
22/03/2023: Sponsor contact was updated.
19/01/2023: Trial's existence confirmed by HSE NorthEast Research Ethics Committee.
